de Jong M, Mahipal M, Ngiam K, Tan W, Yang S, Parameswaran R
Ann R Coll Surg Engl. 2023; 105(7):632-638.
PMID: 37652084
PMC: 10471441.
DOI: 10.1308/rcsann.2022.0094.
Chen S, Jiang X, Zheng W, Luo Y
Diagnostics (Basel). 2023; 13(5).
PMID: 36900093
PMC: 10001029.
DOI: 10.3390/diagnostics13050949.
Chen K, Wang Z, Sun W, Zhang D, Zhang T, He L
Front Endocrinol (Lausanne). 2022; 13:949993.
PMID: 36004350
PMC: 9393698.
DOI: 10.3389/fendo.2022.949993.
Song R, Kim H, Kang K
World J Surg Oncol. 2022; 20(1):170.
PMID: 35643530
PMC: 9148524.
DOI: 10.1186/s12957-022-02629-8.
Kim Y, Kim Y, Bae J, Kim J, Kim K
Cancers (Basel). 2022; 14(10).
PMID: 35625974
PMC: 9139627.
DOI: 10.3390/cancers14102370.
Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.
Seifert R, Schafers M, Heitplatz B, Kerschke L, Riemann B, Noto B
J Nucl Med. 2021; .
PMID: 33771902
PMC: 8612207.
DOI: 10.2967/jnumed.121.261898.
Unilateral Multifocality and Bilaterality Could Be Two Different Multifocal Entities in Patients with Papillary Thyroid Microcarcinoma.
Cai J, Fang F, Chen J, Xiang D
Biomed Res Int. 2020; 2020:9854964.
PMID: 32714990
PMC: 7355378.
DOI: 10.1155/2020/9854964.
Prediction mode of more than 5 central lymph nodes metastases in clinically node-negative ipsilateral papillary thyroid carcinoma with tumor size 1 to 4 cm.
Jin L, Sun H, Zhou L, Xie L, Zhuang Y, Wang J
Medicine (Baltimore). 2020; 99(16):e19809.
PMID: 32311998
PMC: 7440219.
DOI: 10.1097/MD.0000000000019809.
Meta-analysis of risk factors for CCLNM in patients with unilateral cN0 PTC.
Sun W, Zheng B, Wang Z, Dong W, Qin Y, Zhang H
Endocr Connect. 2020; 9(5):387-395.
PMID: 32272445
PMC: 7219143.
DOI: 10.1530/EC-20-0058.
Relationships between clinicopathological prognostic factors in papillary thyroid microcarcinoma: a refined analysis based on 428 cases.
Ciobanu Apostol D, Giusca S, Caruntu I, Lozneanu L, Andriescu E, Moscalu M
Int J Clin Exp Pathol. 2020; 10(8):8944-8956.
PMID: 31966764
PMC: 6965392.
Predictive factors for non-small-volume central lymph node metastases (more than 5 or ≥ 2 mm) in clinically node-negative papillary thyroid carcinoma.
Wang J, Sun Y, Shi L, Xie L
Medicine (Baltimore). 2019; 98(1):e14028.
PMID: 30608456
PMC: 6344183.
DOI: 10.1097/MD.0000000000014028.
Carbon nanoparticles guide contralateral central neck dissection in patients with papillary thyroid cancer.
Yu W, Xu G, Sun J, Zhong N
Oncol Lett. 2018; 16(1):447-452.
PMID: 29963128
PMC: 6019902.
DOI: 10.3892/ol.2018.8691.
Risk factors associated with intrathyroid extension of thyroid microcarcinomas.
Slijepcevic N, Zivaljevic V, Diklic A, Jovanovic M, Oluic B, Paunovic I
Langenbecks Arch Surg. 2018; 403(5):615-622.
PMID: 29770856
DOI: 10.1007/s00423-018-1680-3.
Clinical and pathologic predictors of central lymph node metastasis in papillary thyroid microcarcinoma: a retrospective cohort study.
Gui C, Qiu S, Peng Z, Wang M
J Endocrinol Invest. 2017; 41(4):403-409.
PMID: 28884301
DOI: 10.1007/s40618-017-0759-y.
Association between BRAF mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.
Lu H, Qiu T, Ying J, Lyn N
Oncol Lett. 2017; 13(3):1595-1600.
PMID: 28454296
PMC: 5403221.
DOI: 10.3892/ol.2017.5661.
A meta-analysis on the effect of operation modes on the recurrence of papillary thyroid microcarcinoma.
Yi D, Song P, Huang T, Tang X, Sang J
Oncotarget. 2016; 8(4):7148-7156.
PMID: 27756889
PMC: 5351696.
DOI: 10.18632/oncotarget.12698.
Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status.
Liu N, Meng Z, Jia Q, Tan J, Zhang G, Zheng W
Sci Rep. 2016; 6:34915.
PMID: 27721492
PMC: 5056505.
DOI: 10.1038/srep34915.
Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms.
Vogrin A, Besic H, Besic N, Marolt Music M
Radiol Oncol. 2016; 50(3):269-73.
PMID: 27679542
PMC: 5024656.
DOI: 10.1515/raon-2016-0025.
Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].
Al-Qahtani K, Al Asiri M, Tunio M, Aljohani N, Bayoumi Y, Fatani H
J Otolaryngol Head Neck Surg. 2015; 44:51.
PMID: 26621255
PMC: 4666037.
DOI: 10.1186/s40463-015-0108-0.
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.
Kirwan A, Utratna M, ODwyer M, Joshi L, Kilcoyne M
Biomed Res Int. 2015; 2015:490531.
PMID: 26509158
PMC: 4609776.
DOI: 10.1155/2015/490531.